Skip to content

DMT research published in 2022

Page 2 of 2: studies 21 to 34 of 34, newest first. Back to the DMT overview

Studies

From hallucinations to synaesthesia: A circular inference account of unimodal and multimodal erroneous percepts in clinical and drug-induced psychosis.

Neuroscience and biobehavioral reviews April 2022 Pantelis Leptourgos, Vincent Bouttier, Sophie Denève et al.

Psychedelics distort perception and induce visual and multimodal hallucinations as well as synaesthesia. This is in contradiction with the high prevalence of distressing voices in schizophrenia. Here we introduce a unifying account of unimodal and multimodal erroneous percepts based on circular inference. We show that amplification of top-down predictions (descending loops) leads to an...

In silico study of dimethyltryptamine analogues against 5-HT1B receptor: Molecular docking, dynamic simulations and ADMET prediction

Journal of Herbmed Pharmacology April 1, 2022 Neyder Contreras, Antistio Alvíz-amador, Isabella Manzur-Villalobos 5 citations

Introduction: The 5-HT1B receptor has a potential role in various psychiatric disorders such as depression, anxiety, and post-traumatic stress disorder. The objective of this study was to perform docking and molecular dynamics simulation to evaluate at atomic level the behavior of N,N-dimethyltryptamine (DMT) on 5-HT1B receptor.Methods: In this study, initially, a search for DMT was performed...

A narrative synthesis of research with 5-MeO-DMT.

Journal of Psychopharmacology March 1, 2022 Anna O. Ermakova, Fiona Dunbar, James Rucker et al. 83 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring, short-acting psychedelic tryptamine, produced by a variety of plant and animal species. Plants containing 5-MeO-DMT have been used throughout history for ritual and spiritual purposes. The aim of this article is to review the available literature about 5-MeO-DMT and inform subsequent clinical development. We searched PubMed...

Impact of Two Neuronal Sigma-1 Receptor Modulators, PRE084 and DMT, on Neurogenesis and Neuroinflammation in an Aβ1–42-Injected, Wild-Type Mouse Model of AD

International Journal of Molecular Sciences February 24, 2022 Emőke Borbély, Viktória É Varga, Titanilla Szögi et al. 31 citations

Alzheimer’s disease (AD) is the most common form of dementia characterized by cognitive dysfunctions. Pharmacological interventions to slow the progression of AD are intensively studied. A potential direction targets neuronal sigma-1 receptors (S1Rs). S1R ligands are recognized as promising therapeutic agents that may alleviate symptom severity of AD, possibly via preventing amyloid-β-(Aβ-)...

DOI: 10.3390/ijms23052514 (opens in new tab) Neurogenesis Sigma-1 receptor Neuroinflammation Astrogliosis +2

N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine

Human Psychopharmacology: Clinical and Experimental February 17, 2022 Edward James, Joachim Keppler, Ben Sessa et al. 41 citations

Abstract Objective Reports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post‐traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N‐dimethyltryptamine (DMT) integration with contemporary healthcare. The review also seeks to provide a summary of...

The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)

Journal of Neurochemistry February 12, 2022 Johannes T. Reckweg, Malin V. Uthaug, Attila Szabo et al. 108 citations

Abstract 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) is a naturally occurring tryptamine that primarily acts as an agonist at the 5‐HT1A and 5‐HT2A receptors, whereby affinity for the 5‐HT1A subtype is highest. Subjective effects following 5‐MeO‐DMT administration include distortions in auditory and time perception, amplification of emotional states, and feelings of ego dissolution that...

DOI: 10.1111/jnc.15587 (opens in new tab) Anxiety Agonist Depression economics Pharmacology +1

Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT

Psychopharmacology January 22, 2022 Steven A. Barker 59 citations

As with all drugs, the route, form, and/or dose of a substance administered or applied can play a defining role in its overall pharmacology and use as a therapeutic. This review will focus on these factors as they relate to the psychedelic N,N-dimethyltryptamine (DMT). It will examine the positive and negative aspects of different formulations and routes of administration of DMT and the...

DOI: 10.1007/s00213-022-06065-0 (opens in new tab) Full text (opens in new tab) Pharmacology Hallucinogen Monoamine oxidase inhibitor Oral administration +2

Pharmahuasca and DMT Rescue ROS Production and Differentially Expressed Genes Observed after Predator and Psychosocial Stress: Relevance to Human PTSD.

ACS Chemical Neuroscience January 6, 2022 D. Kelley, Katy Venable, Aspasia Destouni et al. 41 citations

Post-traumatic stress disorder (PTSD) is associated with cognitive deficits, oxidative stress, and inflammation. Animal models have recapitulated features of PTSD, but no comparative RNA sequencing analysis of differentially expressed genes (DEGs) in the brain between PTSD and animal models of traumatic stress has been carried out. We compared DEGs from the prefrontal cortex (PFC) of an...

Ayahuasca for the Treatment of Depression.

Current Topics in Behavioral Neurosciences 2022 Fernanda Palhano-Fontes, Bruno Lobão‐soares, Nicole Leite Galvão‐coelho et al. 25 citations

Ayahuasca, the vine of the souls in Quechua, is a psychedelic brew with a few formulations that most often include the bark of a liana in the Malpighiaceae family (Banisteriopsis caapi), with leaves from a shrub in the coffee family Rubiaceae (Psychotria viridis). Mixed with water and boiled for hours or days, it produces a brownish-colored liquid with a strong and characteristic taste....

Human behavioral pharmacology of psychedelics.

Advances in pharmacology (San Diego, Calif.) 2022 Justin C Strickland, Matthew W Johnson 13 citations

The past decade has witnessed a rapid growth of research on the basic science and clinical understanding of psychedelics. This chapter provides an overview of the human behavioral pharmacology of psychedelics focusing on three prototypic classic psychedelics-psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT). A brief historical overview of the classic psychedelics and...

United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.

International Journal of Drug Policy 2022 Brian S. Barnett, Sloane E Parker, Jeremy Weleff 57 citations

Medicine is currently experiencing a "psychedelic renaissance", said by many to have commenced in 2006. Since then, clinical trials have consistently demonstrated promising findings for psychedelic-assisted therapies in the treatment of various mental health conditions and addictions. While most of this work has been privately funded, governmental biomedical research funding bodies in countries...

Prophylactic action of ayahuasca in a non-human primate model of depressive-like behavior.

Frontiers in Behavioral Neuroscience 2022 Maria Lara Porpino de Meiroz Grilo, Geovan Menezes de Sousa, Lilían Andrade Carlos de Mendonça et al. 12 citations

Observational studies of long-term users of ayahuasca, an Amazonian psychedelic brew, suggest an increase in resilience via improvements in emotion and cognition. Ayahuasca has also demonstrated clinical antidepressant effects in human and animal studies; however, its potential prophylactic action in depression has not been previously studied. Therefore, this experimental study sought to...

DOI: 10.3389/fnbeh.2022.901425 (opens in new tab) Full text (opens in new tab) DMT Callithrix jacchus Depression model Resilience +6